# Grauer & Weil (India) share price today (Grauer & Weil (India) Ltd, NSE: GRAUWEIL)

> Grauer & Weil (India) share price today: ₹74.16 at the NSE close on 3 November 2026, down 12.4% in a year. Grauer & Weil (India) (NSE: GRAUWEIL) is worth ₹3,362 crore, trades at a P/E of 21.0 and has closed between ₹54.68 and ₹88.15 over the past 52 weeks. > Grauer & Weil (India) Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. GRAUWEIL · Speciality Chemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/grauer-weil-indialtd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹74.16 (−12.4% in a year)
- P/E: 21.0× (higher than 54% of the last 11 years)
- Revenue (Jun 2026): ₹299 Cr (+18.2% on a year ago)
- Profit (Jun 2026): ₹40.0 Cr (−9.1% on a year ago)
- Operating margin: 16.0% (−5.0 points on a year ago)
- ROCE: 21%, FY26
- ROIC: 18.6%, against a 12.0% cost of capital: +6.6 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Grauer & Weil (India) share price today? Grauer & Weil (India) Ltd's share price was ₹74.16 at the close on 3 November 2026. It has been moving sideways for 5 weeks. That is 2.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹55 and ₹88, and at that close it sat 58% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 10 weeks in a row. Over the last 11 years the share price moved +530% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Grauer & Weil (India) this quarter? Two changes stood out: revenue up on a year earlier for 4 quarters in a row and operating margin down 5 points on a year earlier. 1. Revenue up on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹299 crore, +18.2% on a year earlier. 2. Operating margin down 5 points on a year earlier 16% in the June 2026 quarter, from 21%. ## What are Grauer & Weil (India)'s latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Grauer & Weil (India) reported revenue of ₹299 crore, up 18.2% from ₹253 crore a year earlier, and a profit of ₹40.0 crore, down 9.1% from ₹44.0 crore. ### Grauer & Weil (India) results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹299 crore | ₹253 crore | +18.2% |
| Profit | ₹40.0 crore | ₹44.0 crore | −9.1% |
| Earnings per share | ₹0.88 | ₹0.96 | −8.3% |
| Operating margin | 16.0% | 21.0% | −5.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Grauer & Weil (India) share price history? Grauer & Weil (India) closed at ₹74.16 on 3 November 2026, down 12.4% from ₹84.69 a year earlier (31 October 2025) and up 139.6% over five years. Its highest weekly close since March 2016 was ₹113.80 on 27 September 2024. ### Grauer & Weil (India) share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹78.00 | −4.9% |
| 1 month ago · 1 Oct 2026 | ₹81.86 | −9.4% |
| 6 months ago · 30 Apr 2026 | ₹69.61 | +6.5% |
| 1 year ago · 31 Oct 2025 | ₹84.69 | −12.4% |
| 3 years ago · 3 Nov 2023 | ₹58.25 | +27.3% |
| 5 years ago · 4 Nov 2021 | ₹30.95 | +139.6% |
| 10 years ago · 4 Nov 2016 | ₹18.78 | +294.9% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹11.78 | +529.5% |
| Highest weekly close since March 2016 · 27 Sep 2024 | ₹113.80 | −34.8% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹11.33 | +554.5% |
| 52-week high (weekly close) · 25 Sep 2026 | ₹88.15 | −15.9% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹54.68 | +35.6% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (565 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Grauer & Weil (India)? 3 Nov 2026: Grauer & Weil (India) closed at ₹74.16, down 4.9% on the week and down 9.4% on the month. 10 Sep 2026: ex-date for a dividend of ₹0.50 a share. ### Earlier

- Results for April to June 2026: Revenue up 18.2% and profit down 9.1% on a year earlier. ## What dividend does Grauer & Weil (India) pay? Grauer & Weil (India) paid ₹0.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.67% at the ₹74.16 close on 3 November 2026. The last was a dividend of ₹0.50 a share, ex-date 10 September 2026. ### Grauer & Weil (India) dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 10 Sep 2026 | ₹0.50 | Dividend |
| 4 Aug 2023 | ₹0.80 | Dividend |
| 14 Sep 2022 | ₹0.65 | Dividend |
| 20 Sep 2021 | ₹0.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 3 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Grauer & Weil (India) Ltd paid out 28% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Grauer & Weil (India) on? Grauer & Weil (India) is on 2 of our India lists: Momentum stocks and Penny stocks. - [Momentum stocks Market cap cr: 3664.030891878426](https://www.sectoralpha.in/momentum-stocks-india)
- [Penny stocks Earnings growth, 12 months (%): 6.65](https://www.sectoralpha.in/penny-stocks-india)

## Is Grauer & Weil (India) profitable? Grauer & Weil (India) Ltd earned ₹40.0 Cr of net profit in the Jun 2026 quarter, −9.1% on the same quarter a year earlier. Full-year FY26 profit was ₹164 Cr. Over 10 years profit has grown 14.6% a year on average. That is 13.4% of the quarter's revenue. The same quarter a year earlier earned ₹44.0 Cr. For the full year, FY26 profit was ₹164 Cr (+4.5% on the year before). Why profit moved: revenue changed +18.2% on a year earlier and the margin moved −5.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +15.0% and revenue +10.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Grauer & Weil (India) make, and is it growing? Grauer & Weil (India) Ltd reported ₹299 Cr of revenue in the Jun 2026 quarter, +18.2% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 10 years it has grown 11.2% a year on average. The last full year, FY26, came in at ₹1,190 Cr. The last four reported quarters add to ₹1,236 Cr. FY26 revenue was ₹1,190 Cr, +5.0% on the year before. Recent pace: the last four quarters grew +10.6% on average, against 11.2% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.1%, against +4.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +6.6%, against +0.3% a year (accelerating). ## How much of every ₹100 of sales does Grauer & Weil (India) keep? Grauer & Weil (India) Ltd's operating margin was 16.0% in the Jun 2026 quarter, 5.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 15.0% and 20.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −4.6 percentage points on the year while gross margin changed −8.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Grauer & Weil (India)'s profit turning into cash? Over the last 3 years, 98% of Grauer & Weil (India) Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹152 Cr of operating cash against ₹164 Cr of profit. After ₹57.0 Cr of spending on assets, ₹95.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 98% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 2.0× depreciation over three years. The next section checks what that spending is building. ## Where does Grauer & Weil (India)'s cash go? Grauer & Weil (India) Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 67 days in FY26, down from 75 days in FY21. It spent ₹134 Cr on assets over the last 3 years. Customers take 54 days to pay, and stock sits for 112 days on average. At FY26 sales of ₹1,190 Cr, each day of that cycle ties up about ₹3.3 Cr, so roughly ₹218 Cr is tied up in the business at any time. FY26: customers took 54 days to pay and stock sat for 112 days, about 3.7 months of sales sitting as stock, for a full cycle of 67 days, shorter than FY21's 75. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 112 days. Customers pay about 54 days after that. Suppliers are paid at 99 days. Together that makes the 67-day cycle. Spending on assets: ₹134 Cr over the last 3 years, against ₹67.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹37.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Grauer & Weil (India)'s P/E ratio, and how does it compare with its own history? Grauer & Weil (India) Ltd's P/E is 21.0×, in the middle of its own history: higher than 54% of past readings. Its usual P/E (the middle reading) is 20.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +4.3% while the price moved −12.4%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +19.1% a year; about +13.0% a year came from earnings growth and about +6.1 percentage points from the multiple (the market paying more); over 10 years the price moved +14.7% a year; about +13.9% a year came from earnings growth and about +0.8 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Grauer & Weil (India) business getting better or worse? Grauer & Weil (India) Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 20.1%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## How much does Grauer & Weil (India) earn on its capital? Grauer & Weil (India) Ltd earned a ROCE of 21% in FY26. That is up from a low of 18% in FY14. Its return on capital used (ROIC) is 6.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.8% net margin and 0.82× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.8% net margin × 0.82× asset turnover × 1.34× leverage (assets divided by equity) ≈ 15.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 18.6% − 12.0% = +6.6 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 18.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 24.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Grauer & Weil (India) have too much debt? Grauer & Weil (India) Ltd has total debt of ₹15.0 Cr against shareholder equity of ₹1,082 Cr as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Grauer & Weil (India) shareholding pattern? No group of Grauer & Weil (India) Ltd's owners changed its stake by a full percentage point over the last two years. Promoters moved +0.0 points over the same period, to 69.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −0.5 points over 8 quarters, to 0.5%; Promoters: +0.0 points over 8 quarters, to 69.0%; Domestic institutions: +0.0 points over 8 quarters, to 0.0%. ## How far is Grauer & Weil (India) from balance-sheet trouble? For Grauer & Weil (India) Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Grauer & Weil (India) rank in its industry? 46.3 out of 100, rank 19 of 30 in Speciality Chemicals, with 96% of the evidence available. Grauer & Weil (India) Ltd scores 46.3 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 19. Relative strength against the index is 14.7%, and revenue and profit growth are weak. The four parts add up to the total exactly: 10.2 + 16.1 + 4.9 + 15.1 = 46.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Grauer & Weil (India) compared with? Grauer & Weil (India) ranks 19 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 46.3 out of 100. 1. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) PANAMAPET · turning · Sector-leading setup · 96% evidence 80.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.8/35 · Revenue 45.9% · Profit 100% · Operating margin change 14 points · 88% evidence Capital efficiency 15.9/25 · ROCE 19.2% · Operating margin 22% · 100% evidence Valuation 19.7/20 · P/E 5.7× · PEG 0.18 · 100% evidence Relative strength 13.9/20 · Lead over its industry 16.3% · Lead over NIFTY 500 31.3% · 1 year 68.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 30.8 + 15.9 + 19.7 + 13.9 = 80.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) YASHO · losing its lead · Most evidence points up · 78% evidence 67.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/35 · Revenue 54.2% · Profit 100% · Operating margin change 3 points · 100% evidence Capital efficiency 12.3/25 · ROCE 8.9% · Operating margin 21% · 100% evidence Valuation 12.7/20 · P/E 45× · PEG 1.02 · 65% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 41.1% · 1 year 103.4% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30 + 12.3 + 12.7 + 12.2 = 67.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Vikram Thermo (India) Ltd](https://www.sectoralpha.in/stocks/vikram-thermo-indialtd) breaking out · Evidence leans up · 68% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 16.9% · Profit 41.9% · Operating margin change 8 points · 83% evidence Capital efficiency 21.3/25 · ROCE 36.2% · Operating margin 48% · 95% evidence Valuation 6.6/20 · P/E 25.8× · PEG n/a · 50% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 74.5% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 21.3 + 6.6 + 12.5 = 64.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) SUNSHIEL · quiet · Evidence leans up · 81% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 12.9% · Profit 100% · Operating margin change 5 points · 88% evidence Capital efficiency 18.8/25 · ROCE 19.9% · Operating margin 16% · 100% evidence Valuation 10.8/20 · P/E 24.3× · PEG 2.21 · 100% evidence Relative strength 10.8/20 · Lead over its industry n/a · Lead over NIFTY 500 4.3% · 1 year -4% · 25% evidence · 0 of 5 weeks ahead Exact sum: 23.6 + 18.8 + 10.8 + 10.8 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Black Rose Industries Ltd](https://www.sectoralpha.in/stocks/black-rose-industries-ltd) BLACKROSE · quiet · Evidence leans up · 81% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 8.6% · Profit 28.6% · Operating margin change 6 points · 88% evidence Capital efficiency 16.4/25 · ROCE 18.7% · Operating margin 16% · 100% evidence Valuation 10.0/20 · P/E 17.1× · PEG 4.96 · 100% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 4.4% · 1 year n/a · 25% evidence · 7 of 12 weeks ahead Exact sum: 23.6 + 16.4 + 10 + 10.9 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Tatva Chintan Pharma Chem Ltd](https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd) TATVA · losing its lead · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 49.2% · Profit 100% · Operating margin change 1 points · 100% evidence Capital efficiency 8.7/25 · ROCE 7.2% · Operating margin 19% · 100% evidence Valuation 11.3/20 · P/E 60.2× · PEG 1.21 · 65% evidence Relative strength 11.4/20 · Lead over its industry 7.8% · Lead over NIFTY 500 23.3% · 1 year 15.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.7 + 8.7 + 11.3 + 11.4 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Aether Industries Ltd](https://www.sectoralpha.in/stocks/aether-industries-ltd) AETHER · leader · Evidence leans up · 90% evidence 59.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 30.2% · Profit 28.4% · Operating margin change 1 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.9% · Operating margin 32% · 100% evidence Valuation 9.7/20 · P/E 85.1× · PEG n/a · 50% evidence Relative strength 14.8/20 · Lead over its industry 22.3% · Lead over NIFTY 500 38.6% · 1 year 114.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.4 + 12.8 + 9.7 + 14.8 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Privi Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/privi-speciality-chemicals-ltd) PRIVISCL · quiet · Evidence leans up · 82% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 17.5% · Profit 44.5% · Operating margin change -1 points · 95% evidence Capital efficiency 18.5/25 · ROCE 22.3% · Operating margin 26% · 76% evidence Valuation 10.1/20 · P/E 33.7× · PEG n/a · 50% evidence Relative strength 7.1/20 · Lead over its industry -9.7% · Lead over NIFTY 500 4.2% · 1 year 10.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 23.7 + 18.5 + 10.1 + 7.1 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) FCL · leader · Evidence leans up · 96% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.3/35 · Revenue 91.5% · Profit 41% · Operating margin change -2 points · 88% evidence Capital efficiency 13.5/25 · ROCE 18.3% · Operating margin 16% · 100% evidence Valuation 5.7/20 · P/E 46.1× · PEG 1.92 · 100% evidence Relative strength 19.5/20 · Lead over its industry 34.1% · Lead over NIFTY 500 48.9% · 1 year 62.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.3 + 13.5 + 5.7 + 19.5 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [DMCC Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/dmcc-speciality-chemicals-ltd) DMCC · quiet · Evidence leans up · 93% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 72.1% · Profit 34.5% · Operating margin change -6.9 points · 100% evidence Capital efficiency 8.7/25 · ROCE 14.8% · Operating margin 4.2% · 100% evidence Valuation 16.1/20 · P/E 16.9× · PEG 0.44 · 65% evidence Relative strength 7.8/20 · Lead over its industry -12.3% · Lead over NIFTY 500 0.9% · 1 year -15.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 22.9 + 8.7 + 16.1 + 7.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Aarti Industries Ltd](https://www.sectoralpha.in/stocks/aarti-industries-ltd) AARTIIND · quiet · Evidence leans up · 100% evidence 55.2 out of 100 Growth Capital Valuation Relative
12. [Galaxy Surfactants Ltd](https://www.sectoralpha.in/stocks/galaxy-surfactants-ltd) GALAXYSURF · leader · Evidence leans up · 81% evidence 53.9 out of 100 Growth Capital Valuation Relative
13. [Pidilite Industries Ltd](https://www.sectoralpha.in/stocks/pidilite-industries-ltd) PIDILITIND · quiet · Evidence leans up · 100% evidence 53.0 out of 100 Growth Capital Valuation Relative
14. [DIC India Ltd](https://www.sectoralpha.in/stocks/dic-india-ltd) DICIND · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative
15. [Kronox Lab Sciences Ltd](https://www.sectoralpha.in/stocks/kronox-lab-sciences-ltd) KRONOX · breaking out · Evidence leans up · 74% evidence 51.8 out of 100 Growth Capital Valuation Relative
16. [Neogen Chemicals Ltd](https://www.sectoralpha.in/stocks/neogen-chemicals-ltd) NEOGEN · leader · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative
17. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) CHEMCON · breaking out · Evidence leans up · 85% evidence 51.1 out of 100 Growth Capital Valuation Relative
18. [Alkyl Amines Chemicals Ltd](https://www.sectoralpha.in/stocks/alkyl-amines-chemicals-ltd) ALKYLAMINE · quiet · Evidence leans down · 96% evidence 47.9 out of 100 Growth Capital Valuation Relative
19. Grauer & Weil (India) Ltd this page GRAUWEIL · breaking out · Evidence leans down · 96% evidence 46.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.2/35 · Revenue 10.1% · Profit 6.6% · Operating margin change -5 points · 88% evidence Capital efficiency 16.1/25 · ROCE 20.6% · Operating margin 16% · 100% evidence Valuation 4.9/20 · P/E 22.7× · PEG 4.02 · 100% evidence Relative strength 15.1/20 · Lead over its industry -0.8% · Lead over NIFTY 500 14.7% · 1 year -5.3% · 100% evidence · 5 of 12 weeks ahead Exact sum: 10.2 + 16.1 + 4.9 + 15.1 = 46.3 · What this means: Relative strength against the index is 14.7%, and revenue and profit growth are weak. 20. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) PAUSHAKLTD · losing its lead · Evidence leans down · 85% evidence 45.8 out of 100 Growth Capital Valuation Relative
21. [Innovassynth Technologies (India) Ltd](https://www.sectoralpha.in/stocks/innovassynth-technologies-indialtd) breaking out · Too little evidence to rank firmly · 53% evidence 44.0 out of 100 Growth Capital Valuation Relative
22. [Anupam Rasayan India Ltd](https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd) ANURAS · turning · Evidence leans down · 78% evidence 43.7 out of 100 Growth Capital Valuation Relative
23. [Platinum Industries Ltd](https://www.sectoralpha.in/stocks/platinum-industries-ltd) PLATIND · turning · Evidence leans down · 81% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Vinati Organics Ltd](https://www.sectoralpha.in/stocks/vinati-organics-ltd) VINATIORGA · quiet · Evidence leans down · 82% evidence 42.4 out of 100 Growth Capital Valuation Relative
25. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) AMAL · quiet · Evidence leans down · 68% evidence 41.5 out of 100 Growth Capital Valuation Relative
26. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) AMNPLST · quiet · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
27. [Transpek Industry Ltd](https://www.sectoralpha.in/stocks/transpek-industry-ltd) TRANSPEK · losing its lead · Evidence leans down · 63% evidence 38.6 out of 100 Growth Capital Valuation Relative
28. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) VISHNU · losing its lead · Evidence leans down · 100% evidence 38.4 out of 100 Growth Capital Valuation Relative
29. [Clean Science & Technology Ltd](https://www.sectoralpha.in/stocks/clean-science-technology-ltd) CLEAN · breaking out · Evidence leans down · 85% evidence 38.1 out of 100 Growth Capital Valuation Relative
30. [Thirumalai Chemicals Ltd](https://www.sectoralpha.in/stocks/thirumalai-chemicals-ltd) TIRUMALCHM · quiet · Most evidence points down · 68% evidence 27.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Speciality Chemicals](https://www.sectoralpha.in/sectors/speciality-chemicals), all 30 compared on one page. ## Which companies are close to Grauer & Weil (India) in size? Grauer & Weil (India) is the 15th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Yasho Industries, Tatva Chintan Pharma Chem and Vishnu Chemicals. Just below it: Panama Petrochem, Innovassynth Technologies (India) and Paushak. ### Speciality Chemicals companies close in size

1. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) ₹3,888 crore
2. [Tatva Chintan Pharma Chem Ltd](https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd) ₹3,845 crore
3. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) ₹3,650 crore
4. Grauer & Weil (India) Ltd ₹3,640 crore
5. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) ₹2,726 crore
6. [Innovassynth Technologies (India) Ltd](https://www.sectoralpha.in/stocks/innovassynth-technologies-indialtd) ₹1,468 crore
7. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) ₹1,450 crore

[All 30 Speciality Chemicals companies, largest first](https://www.sectoralpha.in/sectors/speciality-chemicals#all-companies)

### Companies close in size in other industries

1. [Steamhouse India Ltd](https://www.sectoralpha.in/stocks/steamhouse-india-ltd) ₹3,655 crore
2. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) ₹3,650 crore · Speciality Chemicals
3. Grauer & Weil (India) Ltd ₹3,640 crore
4. [Yash Highvoltage Ltd](https://www.sectoralpha.in/stocks/yash-highvoltage-ltd) ₹3,612 crore · Electric Equipment - General
5. [Kesar India Ltd](https://www.sectoralpha.in/stocks/kesar-india-ltd) ₹3,607 crore · Realty - Construction & Contracting

## What else do people ask about Grauer & Weil (India)? ### What is Grauer & Weil (India)'s share price today? Grauer & Weil (India) Ltd's share price is ₹74.16, −12.4% over the past year. The whole company is worth ₹3,362 Cr on the market. In the last 52 weeks it traded between ₹55 to ₹88; today it is 58% of the way up from the low, 2.1% below its 200-day average (as of 3 November 2026). ### What were Grauer & Weil (India)'s latest quarterly results? Grauer & Weil (India) Ltd reported revenue of ₹299 Cr and net profit of ₹40.0 Cr for the Jun 2026 quarter. Revenue rose 18.2% and profit fell 9.1% compared with a year earlier. Earnings per share were ₹0.88 (as of 3 November 2026). ### What is Grauer & Weil (India)'s market cap? Grauer & Weil (India) Ltd's market capitalisation is ₹3,362 Cr at a share price of ₹74.16. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Grauer & Weil (India) performing? Grauer & Weil (India) Ltd's share price has been moving sideways for 5 weeks. In its latest quarter, revenue rose 18.2% and profit fell 9.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 10 weeks running (as of 3 November 2026). ### Will Grauer & Weil (India)'s share price go up? This page does not forecast Grauer & Weil (India) Ltd's share price. What it shows instead: the share price is ₹74.16, and it has been moving sideways for 5 weeks. Its P/E of 21.0× is higher than 54% of its own last 11 years (as of 3 November 2026). ### Who owns Grauer & Weil (India)? Promoters own 69.0% of Grauer & Weil (India) Ltd, foreign institutions 0.5%, domestic institutions 0.0% and the public 30.4% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Does Grauer & Weil (India) have too much debt? No, Grauer & Weil (India) Ltd has little debt: its debt is 0.01× its equity, and its operating profit is 49 times its interest bill. FY26 borrowings were ₹15.0 Cr against equity of ₹1,081 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Grauer & Weil (India) in its business cycle? Grauer & Weil (India) Ltd's FY26 operating margin was 16.0%, against a 13-year range of 15.0% to 20.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 16.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Grauer & Weil (India) story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Grauer & Weil (India) a stock worth studying right now? What the numbers show: Grauer & Weil (India) Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Penny stocks: https://www.sectoralpha.in/penny-stocks-india

This is research, not advice. We’re not SEBI-registered.